证券代码：000661 证券简称：长春高新 公告编号：2024-098 长春高新技术产业（集团）股份有限公司 董事、监事、高级管理人员薪酬管理办法 第一章 总 则 （三）高级管理人员，包括总经理、副总经理、财务总监、董 事会秘书等《公司章程》规定的高级管理人员，不包括在公司下属 子公司领取薪酬的高级管理人员。在下属子公司领取薪酬的高级管 理人员按子公司薪酬体系执行。 第三条 董事、监事、高级管理人员薪酬的确定遵循以下原则： （一）坚持公司可持续发展的原则； （二）市场化选聘、契约化管理的原则； 1 （三）绩效导向的原则； 第一条 为进一步完善长春高新技术产业（集团）股份有限公 司（以下简称"公司"）治理结构，充分调动董事、监事、高级管理 人员的积极性和创造性，提高企业经营管理水平、完成经营目标任务、 保证公司健康、持续、稳定发展，加强和规范公司董事、监事、高级 管理人员薪酬的管理，实现薪酬分配与公司业绩考核评价的有机结合， 根据《中华人民共和国公司法》、《上市公司治理准则》等有关法律、 法规及《公司章程》的规定，结合公司实际情况，特制定本办法。 第二条 适合本办法的董事、监事、高级管理人员包括： （一）董事， ...

证券代码：000661 证券简称：长春高新 公告编号：2024-096 长春高新技术产业（集团）股份有限公司 关于变更总经理的公告 特此公告 长春高新技术产业（集团）股份有限公司 董事会 2024年9月12日 附件：金磊先生简历 金磊，男，美国加利福尼亚大学博士，现任公司第十一届董事会董事，子 公司长春金赛药业有限责任公司董事、总经理。主要工作经历包括：2014年12月 至2018年10月任长春高新技术产业（集团）股份有限公司董事；1997年4月至今 任长春金赛药业有限责任公司董事、总经理。 金磊先生现持有公司股票4,631,576股，持有公司定向可转换公司债券450 万张，与持有公司百分之五以上股份的股东王思勉女士目前为一致行动人，除此 之外，与公司控股股东、实际控制人、公司其他董事、监事、高级管理人员之间 不存在关联关系；不存在以下情形：（1）《公司法》规定不得担任董事、监事、 高级管理人员的情形；（2）被中国证监会采取证券市场禁入措施，期限尚未届 满；（3）被证券交易所公开认定为不适合担任上市公司董事、监事和高级管理 人员，期限尚未届满；（4）最近三十六个月内受到中国证监会行政处罚；（5） 最近三十六个 ...

| 产品名称 | 胰岛素样生长因子 I(IGF-I)检测试剂盒(荧光免疫层析法) | | --- | --- | | 注册证号 | 沪械注准 20242400294 | | 注册证有效期 | 2024-08-28 至 2029-08-27 | | 预期用途 | 本试剂盒用于体外定量检测血清中胰岛素样生长因子 I(IGF-I)的含量。本试剂盒可对生长紊乱评估起到辅助作 | | | 用。 | 该产品医疗器械注册证的取得，进一步丰富了公司产品线，将对公司业务发 展具有正面影响。公司目前尚无法预测上述产品对公司未来营业收入的影响，敬 请投资者给予关注并注意投资风险。 特此公告 长春高新技术产业（集团）股份有限公司 证券代码：000661 证券简称：长春高新 公告编号：2024-094 长春高新技术产业（集团）股份有限公司 关于获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）下属 公司上海赛增医疗科技有限公司收到上海市药品监督管理局颁发的《医疗器械注 册证》（体外诊断试剂）。具体情况 ...

长春高新技术产业（集团）股份有限公司 关于子公司 GenSci098 注射液获得美国食品药品监督管理局 证券代码：000661 证券简称：长春高新 公告编号：2024-093 受理号：IND171512 新药临床试验申请默示许可的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 根据美国食品药品监督管理局（FDA）相关规则，长春高新技术产业（集团） 股份有限公司（以下简称"公司"）子公司——长春金赛药业有限责任公司（以 下简称"金赛药业"）GenSci098 注射液项目已在美国食品药品监督管理局（以 下简称"FDA"）获得新药临床试验申请默示许可，现将相关情况公告如下： 一、药品的基本情况 产品名称：GenSci098 注射液（人源化抗 TSHR 拮抗型单克隆抗体） 申请事项：在美国境内开展药品临床试验申请 申请人：长春金赛药业有限责任公司 适应症：治疗甲状腺眼病（TED） 二、药品的其它情况 近日，金赛药业已获得 FDA 出具的 IND 确认函，根据函件要求，在收到该 函件后的 30 天内为默示许可期。在达到 FDA 规定的默示许可期末后，该项目即 可开 ...

Investment Rating - The report assigns a "Buy" rating to the company, with a target price of 142.27 CNY per share, compared to the current price of 84.19 CNY [4]. Core Insights - The company reported its 2024 mid-year results, showing a revenue of 6.639 billion CNY (+7.63% year-on-year) and a net profit attributable to shareholders of 1.720 billion CNY (-20.40% year-on-year) [2]. - The growth hormone segment continues to show stable growth, but increased investment during the transformation period has pressured profit margins [2]. - The company is increasing its R&D investment, which reached 1.138 billion CNY (+10.18% year-on-year) in the first half of 2024, indicating a deepening product layout [2]. Financial Summary - For the first half of 2024, the company achieved revenues of 5.152 billion CNY (+0.25% year-on-year) from Jinsai Pharmaceutical, with a net profit of 1.769 billion CNY (-19.49% year-on-year) [2]. - The gross profit margin decreased by 4.13 percentage points to 84.62%, with net profit margin dropping by 8.74 percentage points to 35.42% [2]. - The company forecasts EPS for 2024, 2025, and 2026 to be 10.16 CNY, 11.06 CNY, and 12.43 CNY respectively, with a projected PE ratio of 14 times for 2024 [2][3].

关于子公司聚乙二醇重组人生长激素 新规格新适应症上市申请获得批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 证券代码：000661 证券简称：长春高新 公告编号：2024-092 长春高新技术产业（集团）股份有限公司 产品名称：聚乙二醇重组人生长激素注射液 商品名称：金赛增 受理号：CXSS2300076 规格：27IU/4.5mg/0.5ml/瓶 剂型：注射剂 申请人：长春金赛药业有限责任公司 特纳综合征是由于全部或部分体细胞中一条 X 染色体完全或部分缺失，或 X 染色体存在其他结构异常所致。典型临床表现为：身材矮小、性腺发育不良、 具有特殊的躯体特征（如颈蹼、盾状胸、肘外翻）等，部分伴有自身免疫性疾病 （甲减、糖尿病等）、智力和神经认知功能障碍，对患儿的身心健康造成严重影 响。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）子公 司——长春金赛药业有限责任公司（以下简称"金赛药业"）聚乙二醇重组人生 长激素注射液（以下简称"长效生长激素"）新规格新适应症上市申请获得国家 药品监督管理局（以下简称"国家药监局"）批准。现将相关情 ...

Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Views - The company reported a revenue of 6.639 billion yuan for the first half of 2024, representing a year-on-year increase of 7.63%, while the net profit attributable to shareholders decreased by 20.40% to 1.720 billion yuan [2][3]. - The company is increasing its investment in innovation and transformation, with R&D expenses rising to 1.138 billion yuan, accounting for 17.14% of revenue, up 0.40 percentage points year-on-year [3][4]. Summary by Relevant Sections Revenue and Profitability - The company's revenue for Q1 and Q2 of 2024 was 3.177 billion yuan and 3.461 billion yuan, respectively, showing a year-on-year growth of 14.39% and 2.10% [3]. - The net profit for Q1 and Q2 was 859 million yuan and 861 million yuan, with a year-on-year change of +0.20% and -33.94% [3]. Business Segments - The revenue from overseas and non-pediatric old business has increased, with the sales revenue from international markets for growth hormone products reaching 85.238 million yuan, a year-on-year increase of 267.78% [3]. - The revenue from subsidiary companies includes 5.152 billion yuan from Jinsai Pharmaceutical, 618 million yuan from Baike Biological, and 391 million yuan from Huakang Pharmaceutical, with respective year-on-year growth rates of +0.25%, +10.05%, and +10.37% [3]. R&D and Innovation - R&D investment for the first half of 2024 was 1.138 billion yuan, up 10.18% year-on-year, with 887 million yuan in expense-based R&D and 251 million yuan in capitalized R&D [3]. - New product approvals include recombinant human follicle-stimulating hormone injection and other innovative products, with ongoing clinical trials for long-acting growth hormone products [3]. Financial Forecast and Valuation - The net profit forecasts for 2024-2026 have been adjusted downwards to 4.235 billion yuan, 4.630 billion yuan, and 4.943 billion yuan, reflecting a year-on-year change of -6.55%, +9.32%, and +6.75% respectively [4]. - The current price corresponds to a price-to-earnings ratio of 8 for 2024, 8 for 2025, and 7 for 2026, indicating attractive valuation given the company's operational quality [4].

Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Views - The company reported a revenue of 6.639 billion yuan for the first half of 2024, representing a year-on-year increase of 7.63%, while the net profit attributable to shareholders decreased by 20.40% to 1.720 billion yuan [2][3]. - The company is increasing its investment in innovation and transformation, with R&D expenses rising to 1.138 billion yuan, accounting for 17.14% of revenue, up 0.40 percentage points year-on-year [3][4]. - The revenue structure is shifting, with an increase in the contribution from overseas and non-pediatric businesses, while management expenses surged by 53.71% due to restructuring and increased operational costs [3][4]. Summary by Sections Financial Performance - For Q1 and Q2 of 2024, the company achieved quarterly revenues of 3.177 billion yuan and 3.461 billion yuan, respectively, with year-on-year growth rates of 14.39% and 2.10% [3]. - The net profit for Q1 and Q2 was 859 million yuan and 861 million yuan, showing a decline of 33.94% in Q2 [3]. Revenue Breakdown - The revenue from Jin Sai Pharmaceutical was 5.152 billion yuan, with a net profit of 1.769 billion yuan, down 19.49% year-on-year [3]. - The company saw significant growth in its real estate segment, with revenue increasing by 372.45% to 456 million yuan and net profit rising by 533.17% to 33 million yuan [3]. R&D and Innovation - The company has made progress in launching new products, including several injections and vaccines, with ongoing clinical trials for long-acting growth hormone products [3][4]. - The R&D investment reflects the company's commitment to innovation, with a focus on expanding its product portfolio and enhancing its market position [3][4]. Profit Forecast and Valuation - The profit forecasts for 2024-2026 have been adjusted downward due to uncertainties in growth hormone procurement policies and increased expenses, with projected net profits of 4.235 billion yuan, 4.630 billion yuan, and 4.943 billion yuan, respectively [4]. - The current price corresponds to a price-to-earnings ratio of 8 for 2024, indicating an attractive valuation given the company's operational quality [4].

公司点评报告 · 医药行业 转型升级致利润承压、短期费用投入较高 2024 年中报业绩点评 核心观点 。 事件：2024 年 8 月 15 日，长春高新公布 2024 年半年报，实现营业收入约 66.39 亿元，同比增长 7.63%；归母净利润 17.20 亿元，同比下降 20.40%。 24Q2 实现营收 34.61 亿元，同比增长 2.10%；归母净利润 8.61 亿元，同比下 滑 33.94%。受地产公司结算增加成本、金赛药业转型调整管理架构等原因影 响，上半年归母净利润出现下滑。 。 金赛药业营收持平企稳。2024H1 子公司金赛药业实现收入 51.52 亿元，同 比增长 0.25%，主要由于长效产品放量，营收企稳；实现归母净利润 17.69 亿 元，同比降低 19.49%，主要由于金赛新 BU 管理架构调整导致的管理费用提 升，以及研发投入增加。长期来看，粉针、水针均集采中标，长效产品 PEG 实 现自产自用，同时出海业务呈现良好态势，我们预计生长激素收入和净利润有 望实现稳中有增。 o 金赛药业处于关键转型期，多个产品或有望明年上市。以生长激素为基石， 金賽药业向妇儿健康领域延伸，虽组人促卵泡激素 ...

Investment Rating - The report maintains a "Buy" rating for the company [2] Core Views - The company reported a revenue of 6.639 billion yuan for the first half of 2024, representing a year-on-year increase of 7.63%. However, the net profit attributable to shareholders decreased by 20.40% to 1.720 billion yuan [4] - The company is facing short-term pressure on performance, but its diversified product portfolio is expected to support long-term growth [4] - Increased investment in sales and R&D is noted, with sales, management, and R&D expense ratios rising to 29.12%, 8.31%, and 13.36% respectively in the first half of 2024 compared to the same period in 2023 [4] - The company is actively advancing its innovation strategy, with multiple new product registrations and applications in progress, which lays a foundation for future growth [4] Financial Summary - For 2024, the company is projected to achieve a net profit of 4.016 billion yuan, a decrease of 11.4%, with EPS expected to be 9.93 yuan, corresponding to a P/E ratio of 8.7 [4][6] - Revenue forecasts for 2024-2026 are 15.445 billion yuan, 16.567 billion yuan, and 17.784 billion yuan respectively, with net profits expected to grow to 4.336 billion yuan and 4.700 billion yuan in 2025 and 2026 [6] - The gross margin is projected to decline from 86.0% in 2023 to 83.0% in 2024, stabilizing around 83.3% by 2026 [6]